Purified anti-mouse IL-4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Partially purified native mouse IL-4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C.

Application

ELISA Capture - Quality tested
CyTOF® - Verified
IP, IHC, ICC - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-4 recombinant protein ranging from 250 to 2 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA^1,2,10,13 or ELISPOT⁵ Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization^1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).
Additional reported applications (for the relevant formats) include: immunoprecipitation¹⁶, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections⁸ and paraformaldehyde-fixed, saponin-treated frozen tissue sections^6,7, and immunocytochemistry⁴.
Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)

Product Citations

1. Abdel-Gadir A, et al. 2019. Nat Med. 25:1164. PubMed
2. Lin F, et al. 2019. Sci Adv. 5:eaax1608. PubMed
3. Berber E, et al. 2022. J Virol. 96:e0068822. PubMed
4. Yang WL, et al. 2023. Nat Commun. 14:863. PubMed
5. Zani F, et al. 2023. Nature. 615:705. PubMed
6. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
7. Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed
8. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
9. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
10. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
11. Fang D, et al. 2018. J Exp Med. 215:2705. PubMed
12. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
13. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
14. Crawford G, et al. 2018. Nat Immunol. 1.388194444. PubMed
15. Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed
16. Liu W, et al. 2021. Stem Cell Res Ther. 12:153. PubMed
17. Singh R, et al. 2017. J Immunol. 10.4049/jimmunol.1602010. PubMed
18. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
19. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
20. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
21. Kölle J, et al. 2022. iScience. 25:104440. PubMed
22. Imani J, et al. 2021. JCI Insight. 6:. PubMed
23. Wang Y, et al. 2021. Sci Transl Med. 13:. PubMed
24. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
25. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
26. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
27. He J, et al. 2021. Nat Commun. 12:4371. PubMed
28. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
29. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
30. Tan X, et al. 2021. Mol Microbiol. 116:498. PubMed
31. Di Conza G, et al. 2021. Nat Immunol. 22:1403. PubMed
32. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
33. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
34. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
35. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
36. Xu G, et al. 2007. J Immunol. 179:5358. PubMed
37. Thornton T, et al. 2016. Nat Commun. 7:10553. PubMed
38. Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed
39. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
40. Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed
41. Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed
42. Voehringer C 2009. Blood. 113:2816. PubMed
43. Lee JK, et al. 2021. Cell Mol Immunol. 18:1395. PubMed
44. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
45. Chen YH, et al. 2022. Arthritis Res Ther. 24:27. PubMed

RRID

AB_315315 (BioLegend Cat. No. 504101)
AB_315315 (BioLegend Cat. No. 504102)

Antigen Details

Structure

Cytokine; 15-19 kD (Mammalian)

Bioactivity

Differentiation of naïve CD4⁺ T cells to the T_H2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells

Cell Sources

Mast cells, T cells, bone marrow stromal cells

Cell Targets

B cells, T cells, monocytes, endothelial cells, fibroblasts

Receptors

Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R

Cell Type

Tregs

Biology Area

Immunology

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294.
3. Dullens H, et al. 1991. In vivo 5:567.
4. Paul W. 1991. Blood 77:1859.

Regulation

Upregulated by IL-2, platelet activating factor; downregulated by TGF-β

Gene ID

16189 View all products for this Gene ID

UniProt

View information about IL-4 on UniProt.org

Related Protocols

• Active Protocols: Sandwich ELISA - Video
• Sandwich ELISA Protocol

Other Formats